Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 02, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials".
Press Release Sep 02 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Glenmark Pharmaceuticals Limited has announced the launch of Eribulin Mesylate Injection in single-dose vials through its subsidiary in the USA. This product is bioequivalent to the reference drug Halaven and will begin distribution shortly. The announcement highlights Glenmark's commitment to expanding its product portfolio in the institutional market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
- FY 2024-25
- Q1FY 2025-26
- Press Release Aug 19 2025
- Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)
Later from Glenmark Pharmaceuticals
- Press Release Sep 05 2025
- Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
- Press Release Sep 24 2025
- Glenmark Pharmaceuticals Limited Press Release Oct 23 2025
- Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals